Searching for "Novartis" found 83

ASEAN A roundup of some of the most important recent pharma news from the dynamic ASEAN region, including a big new investment from Novartis in its antibody plant in Singapore, the establishment of ‘pharmaceutical ecozones’ to streamline the drug application process in the Philippines; Vietnam’s journey to attaining WHO Level Four…

Switzerland The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and the licence agreement between EraCal Therapeutics and Novo Nordisk.   Swiss industry welcomes agreement with India, pharma more cautious (Le…

Global Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found herself out of a job.  Now, after joining the boards of several biotechs, including Galapagos, Schaffert returns to big pharma,…

China The biggest pharma industry stories coming out of China, including the impact of the US Biosecure act on Chinese giants WuXi AppTec and WuXi Bio; Novartis’ acquisition of SanReno Therapeutics; the first orphan drug designation for a Chinese herbal medicine-based therapy, and AstraZeneca’s new production line in Taizhou.   Eisai…

APAC The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to shorter reimbursement timelines; Novartis’ early-stage HDAC6 Inhibitor deal with Chong Kun Dang Pharmaceutical; Astellas Pharma’s gastric cancer FDA fail; Daiichi…

Hong Kong Novartis, one of the world’s largest biopharma companies, has secured approval and market access for two of its most advanced cell and gene treatments in Hong Kong. The firm’s territory head, Derek Chang, highlights how early access to innovative therapies in the Hong Kong-Greater Bay Area (GBA) can unlock winning…

UAE Mohamed Ezz Eldin oversees Novartis operations in the UAE, Kuwait, Bahrain, Oman and Qatar. He outlines how the company’s strategy has evolved in the Gulf region following the spin-off of generics arm Sandoz and its now 100 percent focus on innovative medicines. Ezz Eldin also describes some of the key…

Belgium Novartis is one of Belgian pharma’s biggest investors across manufacturing and R&D, contributing EUR 598.9 million to GDP in 2022, creating 4,403 direct and indirect jobs, and reaching 5,349,628 million patients via its locally available portfolio. 18 months into his role as Country President for BeLux, Federico Mambretti expands on…

Egypt Sherif Amin, an 18-year industry veteran with 12 years of experience in oncology leadership roles across MEA, is the recipient of several awards, including the 2019 Oncology President Award, 2015 CEO Innovation Award, and 2014 MENA Leadership Award. A recent appointee as country president for Novartis Egypt, Amin describes how…

Singapore On World Heart Day 2022 Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of cardiovascular disease (CVD) as well as Novartis’ multipronged approach to overcoming healthcare disparities across a diverse region that is home to half the world’s population. Speaking at the outset…

Global After the prolonged underperformance of its generics division, Sandoz, Novartis has announced a spin off that will allow the company to focus on its core business and which is part of a broader paring down strategy. For Novartis, the separation of Sandoz would further support our strategy of building a…

Global Exactly five months after concluding that it was the right time to “monetize” its investment in a cross-town rival – providing Roche “full strategic flexibility” in the process – Novartis has announced a major restructuring; this time, too, citing financial motives.   The Swiss giant – fifth in the global…